Neutralization of mouse interleukin-17 bioactivity inhibits corneal allograft rejection by Chen, XueDong et al.
Neutralization of mouse interleukin-17 bioactivity inhibits corneal
allograft rejection
XueDong Chen,1 ShiYong Zhao,2 XianLing Tang,1 HongYan Ge,1 Ping Liu1
1Eye Hospital, The First Affiliated Hospital of Harbin Medical University, Harbin, China; 2Department of Hepatopancreatobiliary
Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Purpose: To investigate the inhibitory effects of anti-mouse interleukin-17 (IL-17) monoclonal antibody (mAb) in high-
responder corneal allograft rejection.
Methods: C57BL/6 or BALB/c mice corneal grafts were grafted onto BALB/c hosts. The neutralizing mouse IL-17
antibody and isotype control were injected intraperitoneally immediately after transplantation for experimental treatment.
At appropriate times after treatment, recipient grafts were assessed clinically and histologically, and recipient corneal
graft- infiltrating cells were detected by immunohistochemistry and quantified by real-time PCR. The cytokine spleen
levels of T helper type 1 (Th1), Th2, and Th17 were analyzed by enzyme-linked immunosorbent assay. Flow cytometric
analysis was used to evaluate the frequencies of IL-17-producing Th17 cells.
Results: Neutralization of IL-17 with anti-IL-17 mAb obviously prolonged allograft survival compared to the group that
received  isotype  control.  Neovascularizations  and  inflammatory  immune  cells  in  corneal  stroma  decreased  in  the
allogeneic  recipients  treated  with  anti-IL-17  mAb.  The  mRNA  (mRNA)  level  of  graft-infiltrating  cells,  including
neutrophiles, cluster of differentiation 4 (CD4) T cells, and CD8 T cells, decreased dramatically in the IL-17 neutralization
group. At days 14 and 42, splenocytes from recipients treated with anti-IL-17 mAb produced significantly less of the pro-
inflammatory cytokines interferon-gamma (IFN-γ), IL-12p40, and IL-17 compared to those from control Ig-treated
recipients at day 14. However, Th2 cytokine IL-4 and IL-5 production increased, and IL-13 levels were not significantly
different among the three groups. IL-6 production was elevated in recipients treated with anti-IL-17 mAb. Anti-IL-17
mAb reduced the percentage of Th17 in CD4+ T cells, but there was no statistical significance between anti-IL-17 mAb
and the control group.
Conclusions: Neutralization of mouse IL-17 bioactivity with anti-IL-17 mAb improves allogeneic corneal graft survival
and inhibits corneal allograft rejection to a certain extent by inhibiting production of graft-infiltrating inflammatory cells
and decreasing the secretion of pro-inflammatory cytokines.
Corneal  allografts  enjoy  high  rates  (40%–50%)  of
spontaneous  acceptance  compared  with  other  types  of
transplantation [1]. Allograft rejection is the main cause of
corneal  graft  failure.  The  5-year  survival  rate  of  low-risk
keratoplasty  is  approximately  90%,  even  without  human
leukocyte-antigen matching [2]. In contrast, the survival rate
of high-risk keratoplasty decreases significantly to below 50%
due to immune-mediated rejection [3,4]. Allograft rejection is
histologically characterized by a massive infiltration of T
cells, especially cluster of differentiation 4 (CD4) T cells,
which play an important role in the response to allogeneic
corneal cells [5]. Existing information [6-8] on the molecular
mechanisms  governing  the  interactions  between
immunocompetent  cells  indicates  that  cytokines  play  an
important  role  in  the  maintenance  of  graft  inflammation,
tissue destruction, and rejection.
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Both T helper type 1 (Th1) and Th2 responses in acute
allograft rejection have been investigated. Th1 cells, which
mediate rejection, are mainly associated with mononuclear
cell infiltration of the grafts, and they characteristically secrete
interferon-gamma (IFN-γ) and express transcription factor T-
bet  (T-bet).  Th2  cells,  which  are  involved  in  inducing
transplantation tolerance, are generally related to eosinophil
infiltration of the grafts and produce interleukin-4(IL-4), IL-5,
and IL-13 [9-12]. Recently, the Th1/Th2 paradigm has been
challenged  by  the  finding  that  Th17  may  participate  in
transplant immunity. Th17 cells produce large amounts of
IL-17, IL-17 F, IL-21, and IL-22. In addition, transforming
growth factor beta (TGF-β), IL-6, and IL-21 may induce naive
T cells to differentiate into Th17 cells under the influence of
the orphan nuclear receptor, retinoid related orphan receptor
gammat (RORγt) [13].
IL-17 is a potent pro-inflammatory cytokine that induces
chemokine expression and leukocyte infiltration and mediates
tissue  inflammation  [14].  IL-17  has  been  implicated  in
allograft rejection of renal [15,16], cardiac [17,18], lung [8,
19-21], and vascular [22] tissues. Many recent studies have
focused  on  the  effect  of  IL-17  antagonists  on  allograft
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2148rejection. It was reported that an IL-17 antagonist prolonged
nonvascularized and vascularized cardiac allograft median
survival  time  [23],  and  IL-17  neutralization  inhibited
accelerated cardiac allograft rejection in a model of chronic
allograft vasculopathy in T-bet−/− mice [24]. IL-17 antagonism
inhibits  acute  but  nonchronic  vascular  rejection  [22].
However, little is known about the therapeutic efficacy of
IL-17  neutralization  in  acute  murine  corneal  allograft
rejection.
METHODS
Mice and anesthesia: Animals were 6- to 8-week-old female
BALB/c and C57BL/6 mice provided by the Experimental
Animal  Center  of  the  First  Affiliated  Hospital  of  Harbin
Medical  University  (Harbin,  China),  and  all  animal
procedures were approved by the animal care board. Animals
were treated according to the Association for Research in
Visio and Ophthalmology Statement on the Use of Animals
in Ophthalmic and Vision Research. Each animal was deeply
anesthetized  by  intraperitoneal  injection  of  3  to  4  mg  of
ketamine and 0.1 mg of xylazine.
Corneal transplantation and the evaluation of graft survival:
Penetrating  keratoplasty  in  mice  has  been  described
previously [25]. Briefly, C57BL/6 or BALB/c donor corneal
grafts with 2-mm diameters were excised and placed in the
same sized BALB/c recipient beds with eight interrupted 11–
0 nylon sutures (Huawei, Hangzhou, China). The grafts were
examined  by  slit-lamp  biomicroscopy  twice  a  week  and
scored  using  a  previously  described  scoring  system  [26].
Briefly, grafts that received an opacity score of 2+ or greater
(mild, deep stromal opacity with pupil margin, and iris vessels
visible) at 3 weeks or 3+ or greater (moderate stromal opacity
with  only  the  pupil  margin  visible)  at  2  weeks  after
transplantation  were  considered  rejected  (immunologic
failure).
Treatment with antibody: The neutralizing mouse IL-17 mAb
and isotype control (R&D systems, Minneapolis, MN) were
used  for  treatment.  The  recipients  were  injected
intraperitoneally  with  0.1  mg  anti-IL-17  mAb  or  isotype
control daily on days 0–3, followed by every other day until
day 13 after transplantation [24].
Histologic analysis: Recipients grafts were fixed and frozen
in liquid nitrogen. The 4-µm frozen sections were fixed in
acetone for 10 min and air dried. Slides were stained with rat
antimouse Ly6G (neutrophils), CD4 (CD4+ T cells), and CD8
(CD8+ T cells) antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA), then with goat antirat FITC (ZSGB-BIO, BeiJing,
China)  as  secondary  antibodies.  FITC-conjugated  rat
antimouse CD11b antibody (BD PharMingen, San Diego,
CA) was used to detect the recruitment of macrophages. For
histologic  assessment,  corneal  grafts  were  fixed  in  10%
neutral-buffered formalin and 4-µm sections were routinely
stained by hematoxylin and eosin.
Quantitative real-time PCR: The mRNA level of granulocyte
differentiation  antigen  1  (Gr-1;  neutrophils),  macrophage
differentiation antigen-1 (Mac-1; macrophages), CD4 (CD4+
T cells), and CD8 (CD8+ T cells) in recipients grafts was
detected by real-time PCR. Total RNA was extracted from
corneal tissue, using the TRIZOL reagent (Invitrogen, Foster
City, CA). Total RNA was quantified using an ultraviolet
spectrophotometer, and 0.5 μg of total RNA was subsequently
processed to cDNA by reverse transcription. Real-time PCR
was performed on cDNA. Primer-binding DNA was detected
by  EVA  green  dye  (BioRad,  Hercules,  CA).  Relative
expression  of  the  gene  of  interest  was  expressed  as  the
comparative concentration of the product compared with β-
actin  (Actb)  product,  as  calculated  by  the  MxPro  QPCR
software (Agilent Technologies, Santa Clara, CA).
Enzyme-linked immunosorbent assay (ELISA): Spleens from
recipients of corneal grafts were harvested for ELISA. The
supernatant  was  collected,  and  IFN-γ,  IL-4,  IL-5,  IL-6,
IL-12p40,  IL-13,  and  IL-17  production  was  determined
according to the manufacturer’s instructions. The levels of
IFN-γ and IL-17 in spleens were quantified using the ELISA
kit for murine IL-17 and IFN-γ (R&D systems). IL-4, IL-5,
IL-6, IL-12p40, and IL-13 production was quantified using
murine IL-4, IL-5, IL-6, IL-12p40, and IL-13 antibody pairs
for  ELISA  (BD  PharMingen).  All  measurements  were
performed in duplicate.
Flow cytometry: Spleens were retrieved, mashed, and then
erythrocytes were lysed. Cells were stained extracellularly
with antimouse CD3 PerCP-Cy5.5, antimouse CD4 FITC, and
appropriate isotype control mAb (eBioscience, San Diego,
CA) as per the manufacturer’s instructions. Splenocytes were
fixed  and  permeabilized  with  fixation/permeabilization
solution (BD PharMingen) according to the manufacturer’s
instructions and then stained intracellularly with antimouse
IL-17  APC  and  appropriate  isotype  control  mAb
(eBioscience) in the dark for 30 min. Data collection and
analysis were performed on a FACS Calibur flow cytometer
using CellQuest software (BD Bioscience).
Statistics: For graft survival, the log-rank test was used to
calculate p values. For other experiments, data were calculated
as mean±SEM, and Student t test was used to compare mean
values. All statistical analyses were performed using SPSS
13.0 software (SPSS, Chicago, IL). A p value <0.05 was
considered statistically significant.
RESULTS
Neutralizing  interleukin-17  antibody  delayed  corneal
allograft  rejection:  We  administered  anti-IL-17  mAb  or
control Ig to syngeneic and allogeneic recipients and observed
the grafts to determine the effect of IL-17 neutralization on
graft survival time. Our results showed that all of the corneal
syngenic grafts survived for 56 days after transplantation and
that neutralization of IL-17 with anti-IL-17 mAb did not affect
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were rejected at 20 days after transplantation in the control
group. Results from Kaplan–Meier survival curves showed
that  neutralization  of  IL-17  with  anti-IL-17  mAb  indeed
prolonged allograft survival time compared with the group
that received control IgG (Figure 1A). Pathological results
showed that the normal corneal endothelium was intact and
that  no  inflammatory  cells  existed  in  corneal  stroma.
However, we found that the corneal stroma were edema, and
inflammatory cells were present in thickened stroma after
syngeneic or allogeneic transplantation. Moreover, massive
neovascularizations were found in allogeneic corneal stroma.
In  syngeneic  groups,  the  edema  in  cornea  from  IL-17
antibody-treated recipients was improved compared to edema
in  cornea  from  control  Ig-treated  recipients  after
transplantation.  In  contrast,  corneal  endothelium  of  grafts
from allogenic recipients treated with IL-17 antibody was
more intact and neovascularization and inflammatory cells in
the stroma decreased significantly compared to control Ig-
treated recipients (Figure 1B-H).
Neutralizing  interleukin-17  antibody  inhibited  graft-
infiltrating  cell  expression  after  corneal  allogeneic
transplantation: Massive inflammatory cells were present in
the  corneal  stroma  after  transplantation.  Neutrophils,
macrophages,  CD4+  T  cells,  and  CD8+  T  cells  were
predominant in corneal allografts at 2 weeks after surgery, and
neutrophils were mainly in corneal syngeneic grafts (Figure
2A-J). To determine whether the delayed allograft rejection
in the group treated with anti-IL-17 mAb correlated with
decreased infiltration of inflammatory cells, the mRNA level
of graft-infiltrating cells was detected by real-time PCR. We
found that Gr-1, CD4, and CD8 expression in the inflamed
allografts of anti-IL-17 mAb treatment recipients (2.22±0.1,
1.64±0.04,  and  0.04±0.1,  respectively)  decreased
Figure 1. Interleukin-17 neutralization
delayed corneal allograft rejection.
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2150significantly  compared  to  those  of  control  recipients
(3.61±0.08, 2.69±0.06, and 2.17±0.04, respectively; p<0.01)
on day 14 after transplantation. In contrast, Mac-1 expression
did  not  alter  appreciably  (1.39±0.06  versus  1.44±0.07;
p=0.519). In syngeneic corneal grafts treated with anti-IL-17
mAb,  Gr-1  expression  did  not  decrease  significantly
compared to control grafts on day 14 after transplantation
(2.32±0.05 versus 2.44±0.06; p=0.141; Figure 2K-L).
Neutralizing  interleukin-17  antibody  inhibited  pro-
inflammatory cytokine expression after corneal allogeneic
transplantation: We examined the production of Th1-, Th2-,
and Th17-related cytokines in the anti-IL-17 mAb or control
Ig-treated recipients of corneal spleens 14 or 42 days after
Figure 2. Interleukin-17 neutralization
inhibited  graft-infiltrating  cells
expression  at  day  14  after  corneal
allogeneic transplantation.
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2151transplantation. We found that at days 14 and 42, splenocytes
from  allogeneic  recipients  treated  with  anti-IL-17  mAb
produced  significantly  less  pro-inflammatory  cytokines
compared to control Ig-treated recipients at day 14 (IFN-γ
[529.8±13.83  and  636.5±9.34  versus  741.48±10.51,
respectively],  IL-12p40  [539.58±10.74  and  750.62±8.00
versus  1156.9±69.93],  and  IL-17  [173.7±8.11  and
273.6±10.08 versus 366.13±7.93; p<0.01]). In contrast, Th2
cytokines  IL-4  (420.25±4.47  and  267.76±5.34  versus
248.69±5.67, respectively; p<0.05) and IL-5 (425.38±5.91
and  343.5±6.14  versus  262.06±5.27;  p<0.01)  production
increased in splenocytes from recipients treated with anti-
IL-17  mAb  compared  to  the  control  Ig-treated  recipients.
However, IL-13 levels (367.48±5.05 and 363.74±6.55 versus
359.87±4.81;  p=0.31  and  p=0.65,  respectively)  were  not
significantly  different  from  the  control  group.  IL-6
(887.17±16.36  and  620.28±11.09  versus  537.35±12.01,
respectively; p<0.01) production was elevated in recipients
treated with anti-IL-17 mAb (Figure 3). Interestingly, the
above  cytokines  were  not  found  in  splenocytes  from
syngeneic recipients treated with anti-IL-17 mAb or control
IgG at days 14 and 42 after transplantation.
Neutralizing  interleukin-17  antibody  did  not  reduce  the
percentage of CD4+ Th17 cells: For the allogeneic recipients,
the percentage of CD4+ IL-17+ in CD4+ cells in the isotype
control, anti-IL-17 mAb (day 14), and anti-IL-17 mAb (day
42)  groups  (7.73±0.55%,  7.12±0.64%,  and  7.63±0.46%,
respectively) increased markedly compared with the normal
group  (0.31±0.05%;  p<0.01).  Although  the  percentage  of
CD4+  IL-17+  in  CD4+  cells  in  the  anti-IL-17  mAb  group
trended lower than that of the isotype control group, there were
no  significant  differences  among  them  (p>0.05).  In  the
syngeneic recipients, there were no significant differences in
the  isotype  control  (0.43±0.07%),  anti-IL-17  mAb
(0.36±0.05%), and normal group (0.31±0.05%) (p=0.17 and
p=0.41, respectively; Figure 4A-B).
DISCUSSION
Although many studies have demonstrated the effect of IL-17
on allograft rejection, controversy still exists regarding the
role of IL-17 in corneal transplant rejection. A pathogenic role
of IL-17 at the early stage of corneal allograft rejection has
been described by Chen et al. [27], while Yamada et al. [28]
thought  that  IL-17  did  not  have  a  critical  role  in  the
development of minor specific allograft rejection in C57BL/
6 mice. However, Cunnusamy et al. [29] argued that IL-17A
is not required for corneal allograft rejection and may instead
contribute to the immune privilege of corneal allografts. Our
study supports the pathogenic role of IL-17 in corneal allograft
rejection.  This  discrepancy  may  be  attributed  to  different
timing when the target gene was detected and a different
model  of  corneal  transplantation.  In  our  study,  we
demonstrated  the  effects  of  antimouse  IL-17  antibody
treatment on corneal allograft rejection at 14 and 42 days after
transplantation in a wild-type murine corneal transplant model
instead of an IL-17 knockout murine keratoplasty model as
shown by other reports. We then analyzed the relationships of
delayed  allograft  rejection  with  decreased  infiltration  of
inflammatory cells and pro-inflammatory cytokines.
Our  results  showed  that  neutralizing  IL-17  antibody
significantly improved the survival rate of corneal allogeneic
transplantation  but  had  no  effect  on  the  survival  time  of
syngeneic  grafts.  Consistently,  histological  analysis  of
corneal allografts revealed that neutralizing IL-17 antibody
decreased  tissue  damage  and  decreased  graft-infiltrating
neutrophil, CD4+ T-cell, and CD8+ T-cell expression. We
found that neutrophils increased due to inflammation during
the early postoperative period, and CD4+ and CD8+ T cells
Figure 3. Interleukin-17 neutralization
inhibited  proinflammatory  cytokine
expression  after  corneal  allogeneic
transplantation.
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2152mediated the T-cell response in rejecting mice due to the
adaptive immune response. Neutrophil depletion by anti-Gr1
antibody  injections  significantly  delayed  MHC  class  II
incompatible  skin  allograft  rejection  in  IL-4-deficient
recipients  [30].  Similarly,  neutrophil  depletion  delayed
cardiac allograft rejection in IFN-deficient mice [31]. Anti-
CD4/CD8 mAbs greatly reduced the prevalence of cardiac
allograft  vasculopathy  and  eliminated  the  development  in
mice rendered tolerant by the induction of mixed chimerism
[32]. These findings suggest that neutrophils, CD4+ T cells,
and CD8+ T cells play an important role in allograft rejection.
Furthermore,  the  results  of  mRNA  detection  of  these
inflammatory cells proved that delayed allograft rejection in
recipients treated with anti-IL-17 mAb was correlated with
decreased infiltration of inflammatory cells. All the above
results  indicate  that  IL-17  neutralization  might  delay  the
development  of  corneal  allograft  rejection  by  inhibiting
inflammation,  particularly  neutrophil  infiltration  and  that
anti-IL-17 mAb has a protective effect on corneal rejection.
Interestingly,  neutralizing  IL-17  antibody  decreased  the
corneal injury in syngeneic transplantation, but inflammatory
graft-infiltrating cells had no notable decrease at 14 days after
transplantation.  We  attribute  this  to  different  timing  of
inflammatory cell detection. As a course of inflammation,
syngeneic corneal transplantation did not reject. At the early
stage of syngeneic transplantation, neutrophils were present
and  subsequently  decreased  with  the  disappearance  of
inflammation.
We  also  found  that  delayed  allograft  rejection  was
associated with decreased pro-inflammatory cytokines IFN-
γ, IL-12p40, and IL-17 after IL-17 neutralization. Th1- and
Th2-cell subsets appear to negatively regulate differentiation
of  Th17  cells  [33].  IL-12  and  IFN-γ  have  been  found  to
suppress IL-17 production [34]. The addition of IL-12, IFN-
γ, or IL-4 to cultures inhibits either IL-23- or TGF-β- and IL-6-
stimulated differentiation of mouse and human Th17 cells
[35-38]. IL-23, described as the pairing of the p19 subunit with
the p40 subunit and shared with IL-12 [39], promotes IL-17
expression and the proliferation of IL-17-producing cells from
a pool of memory T cells [34,40]. IL-12 is an important factor
for Th1 cell development. These two related cytokines initiate
and  sustain  Th1  cell-mediated  immune  responses  [41].
However, in recipients treated with anti-IL-17 mAb, although
IL-12p40  production  decreased  significantly,  IL-23
production by splenocytes was minimal, indicating that IL-23-
independent  mechanisms  may  be  responsible  for  the
maintenance of the Th17 response [42]. In contrast, some
papers have shown pathogenic roles of IFN-γ and IL-17 in
corneal immune rejection of orthotopic allografts in mice and
rats  [27,42,43].  We  hypothesize  that  reducing  IFN-γ  and
IL-17  levels  would  block  allograft  rejection,  which  is
consistent with our results in that delayed-rejected recipients
with anti-IL-17 mAb treatment, IFN-γ and IL-17 production
from splenocytes decreased significantly. Interestingly, IL-6
production was elevated after IL-17 neutralization, suggesting
that IL-6 is upstream of IL-17 in the Th17 differentiation
pathway. Production of Th2 cytokines IL-4 and IL-5 was also
increased with IL-17 neutralization, indicating that IL-17 is
critical for mediating corneal allograft rejection.
Of the large number of cell types analyzed for IL-17
expression, the CD4+ T cells have been previously reported to
be  the  only  producer  of  IL-17  [44-46].  However,  recent
reports have suggested that IL-17 is produced by Th17, natural
killer, natural killer T, γδT, neutrophils, and CD8+ T cells
[47-49]. In our study, we focused on Th17. In agreement with
previous reports [50], we found that CD4+ T cells derived from
spleens expressed IL-17 in allogeneic recipients, but there was
very little or no IL-17 expression in syngeneic recipients and
Figure 4. The percentages of CD4+Th17 cells in spleens.
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expression decreased with IL-17 neutralization, but there were
no significant differences among control and anti-IL-17 mAb
groups. Although pro-inflammatory cytokines that regulate
Th17  cell  differentiation  changed  correspondingly,  IL-17
neutralization has no effect on the frequency of Th17 cells.
In summary, our results indicate that IL-17 neutralization
significantly  prolongs  corneal  allograft  survival  time  and
inhibits  corneal  allograft  rejection  to  a  certain  extent  by
inhibiting production of graft-infiltrating inflammatory cells
and  decreasing  secretion  of  pro-inflammatory  cytokines.
These findings may offer new treatment options for corneal
rejection and other immune system transplantation concerns.
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